Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.
2. Pelland-Marcotte MC, Carcao MD. Hemophilia in a changing treatment landscape. Hematol Oncol Clin North Am. 2019;33(3):409–23.
3. Ljung R, Auerswald G, Benson G, et al. Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. Eur J Haematol. 2019;102(2):111–22.
4. Genentech Inc. Hemlibra® (emicizumab-kxwh) injection, for subcutaneous use: US prescribing information. 2018.
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2483adba-fab6-4d1b-96c5-c195577ed071
. Accessed 9 Sept 2019.
5. Chugai Pharmaceutical Co Ltd. Chugai’s Hemlibra® subcutaneous injection receives approval for hemophilia A without inhibitors and extension of dosing interval [media release]. 21 Dec 2018.
http://www.chugai-pharm.co.jp/english/news/detail/20181221153002_580.html
.
Cited by
45 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献